193 related articles for article (PubMed ID: 25835106)
1. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
2. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
3. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
[No Abstract] [Full Text] [Related]
4. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features, cellular differentiation, PCNA and P53 expressions in gastrointestinal stromal tumors.
Can B; Sökmensüer C
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxliii-ccxlviii. PubMed ID: 15244191
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of p16INK4a and p53 overexpression in endocrine tumors of the gastrointestinal tract.
Li AF; Tsay SH; Liang WY; Li WY; Chen JY
Am J Clin Pathol; 2006 Dec; 126(6):856-65. PubMed ID: 17074692
[TBL] [Abstract][Full Text] [Related]
7. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
[TBL] [Abstract][Full Text] [Related]
8. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract.
Furlan D; Cerutti R; Uccella S; La Rosa S; Rigoli E; Genasetti A; Capella C
Clin Cancer Res; 2004 Feb; 10(3):947-57. PubMed ID: 14871972
[TBL] [Abstract][Full Text] [Related]
9. Endocrine tumors of the gut and pancreas tumor biology and classification.
Rindi G; Klöppel G
Neuroendocrinology; 2004; 80 Suppl 1():12-5. PubMed ID: 15477709
[TBL] [Abstract][Full Text] [Related]
10. CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma.
Erler BS; Presby MM; Finch M; Hodges A; Horowitz K; Topilow AA; Matulewicz T
Tumour Biol; 2011 Feb; 32(1):107-11. PubMed ID: 21058037
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers.
Llombart B; Monteagudo C; López-Guerrero JA; Carda C; Jorda E; Sanmartín O; Almenar S; Molina I; Martín JM; Llombart-Bosch A
Histopathology; 2005 Jun; 46(6):622-34. PubMed ID: 15910593
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
[TBL] [Abstract][Full Text] [Related]
13. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine neoplasms arising in inflammatory bowel disease: a report of 14 cases.
Sigel JE; Goldblum JR
Mod Pathol; 1998 Jun; 11(6):537-42. PubMed ID: 9647591
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry and c-kit gene analysis in determining malignancy in gastrointestinal stromal tumors.
Yamaguchi M; Tate G; Endo Y; Miyaki M
Hepatogastroenterology; 2003; 50(53):1431-5. PubMed ID: 14571755
[TBL] [Abstract][Full Text] [Related]
16. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract.
Fahrenkamp AG; Wibbeke C; Winde G; Ofner D; Böcker W; Fischer-Colbrie R; Schmid KW
Virchows Arch; 1995; 426(4):361-7. PubMed ID: 7599788
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
19. Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors.
Al-Khafaji B; Noffsinger AE; Miller MA; DeVoe G; Stemmermann GN; Fenoglio-Preiser C
Hum Pathol; 1998 Sep; 29(9):992-9. PubMed ID: 9744317
[TBL] [Abstract][Full Text] [Related]
20. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.
Shida T; Kishimoto T; Furuya M; Nikaido T; Koda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Tanizawa T; Nakatani Y; Miyazaki M
Cancer Chemother Pharmacol; 2010 Apr; 65(5):889-93. PubMed ID: 19657638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
